A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 administered by Bilateral Intrathalamic Infusion in Subjects with Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)